Michael Sapienza: FDA Approves Nivolumab/Ipilimumab for Colorectal Cancer
Michael Sapienza, Chief Executive Officer at Colorectal Cancer Alliance, shared the following insightful post on LinkedIn:
“Recent new developments in colorectal cancer treatment show promise for the future and reinforce that research funding is needed to continue making progress.
Yesterday, the FDA approved a combination therapy from Bristol Myers Squibb Myers Squibb of nivolumab (Opdivo) with ipilimumab (Yurvoy) for dMMR/MSI-H metastatic colorectal cancer. Read more here.
The National Institutes of Health (NIH) research was published in the journal Nature Medicine. The findings show promising results for a new combination therapy that significantly shrank multiple liver metastases in a patient with rectal cancer. Read more here.
More research and approvals like these are necessary to help all colon and rectal cancer patients whose treatment options are limited. The Colorectal Cancer Alliance Cancer Alliance is committed to funding innovative research through its Project Cure CRC initiative. Your support of life-saving research is needed now more than ever. Visit here to get involved.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023